What does the research actually show about lithium and brain aging?
Laboratory and observational studies suggest lithium might influence several processes linked to Alzheimer's disease, including reducing abnormal tau protein tangles and amyloid plaques, calming brain inflammation, and protecting synapses [4]. However, these are biological clues, not proof that a microdose pill prevents memory loss in people. The strongest evidence for lithium's brain effects comes from its established use at much higher doses for mood disorders—not from studies of microdoses in aging adults without psychiatric conditions [3][4].
A 2026 review of studies published between 2017 and 2025 concluded that chronic exposure to low or trace doses of lithium was associated with delayed cognitive decline and reduced disease incidence in some populations, but it also stated that evidence from randomized trials remains inconclusive [4]. This means the promising signals come from observational studies, which can show correlation but not causation.
Is there a clinical trial testing lithium microdoses for cognitive decline?
Yes, but it has not yet reported results. A randomized, double-blind, placebo-controlled trial is currently enrolling 250 participants aged 55–75 with mood disorders (bipolar disorder or recurrent depression) to test a daily 50 mg lithium tablet (a trace dose) versus placebo over five years [3]. The primary outcome is the development or worsening of mild cognitive impairment (MCI). This is the only study in this set that directly tests the question you asked, but because it is a protocol paper describing a trial that is still in progress, there are no results to report yet [3]. The answer to your question will become clearer once this trial and others like it publish their findings.
What do the strongest studies on preventing cognitive decline tell us?
The largest and most rigorous trials in this collection tested other interventions and found no significant benefit. A 3-year randomized controlled trial of the MIND diet in 604 older adults with a family history of dementia found that the diet group improved by 0.205 standardized units on a global cognition score, while the control group improved by 0.170 units—a difference so small it was not statistically significant (P=0.23) [1]. Similarly, a 1-year randomized trial of testosterone therapy in 788 men aged 65 and older found no improvement in cognitive function [5]. These results highlight how difficult it is to demonstrate cognitive benefit in well-designed trials, even with interventions that have strong observational support.
On the other hand, a large observational study of 619 older nuns followed for an average of 8.6 years found that 30% of those diagnosed with mild cognitive impairment (MCI) later reverted to normal cognition, and higher cognitive reserve (measured by education and language skills) more than doubled the likelihood of reverting versus progressing to dementia [2]. This suggests that lifestyle and lifelong learning may be more powerful than any single drug for maintaining cognitive health.
About These Sources
This answer is built on 5 peer-reviewed studies — published from 2022 to 2026, 2 from 2024 or later, 2 in Q1 journals, collectively cited 324 times — selected as the most relevant from 7 studies that passed quality screening, drawn from 77 papers retrieved from a database of over 500 million.
Sources used in this answer
Trial of the MIND Diet for Prevention of Cognitive Decline in Older Persons
In a 3-year randomized controlled trial of 604 older adults, the MIND diet did not significantly improve global cognition scores compared to a control diet (mean difference 0.035 standardized units, P=0.23), and brain MRI measures were similar between groups.
Cognitive Reserve and Mild Cognitive Impairment
In a cohort of 619 nuns aged 75+ followed for up to 12 assessments, 30% of those with mild cognitive impairment reverted to normal cognition, and higher education more than doubled the likelihood of reversion versus progression to dementia.
Trace-dosage of lithium for prevention of cognitive declining in mood illnesses: a randomized double-blind, placebo-controlled, study protocol
This is a protocol for an ongoing randomized, double-blind, placebo-controlled trial testing 50 mg daily lithium versus placebo in 250 adults aged 55–75 with mood disorders over 5 years; no results are yet available.
LITHIUM AND ALZHEIMER’S DISEASE: NEUROBIOLOGICAL MECHANISMS, ETHICAL IMPLICATIONS, AND SOCIAL PERSPECTIVES ON COGNITIVE AGING
A 2026 review of preclinical and early clinical studies concluded that low/trace lithium doses are associated with delayed cognitive decline in some populations, but evidence from randomized trials remains inconclusive.
Testosterone, cognitive decline and dementia in ageing men.
In a 1-year randomized placebo-controlled trial of 788 men aged 65+ with low testosterone, testosterone treatment improved sexual function but did not improve cognitive function.